OTC Markets
Prev Close 0.16
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.19
Exchange OTC Markets
Shares Outstanding 28.83B
Market Cap 4.58M
Div & Yield N.A. (N.A)
Icahn Boosts ImClone Stake

Icahn Boosts ImClone Stake

The investor now holds an 11.68% interest in the Erbitux maker.

ImClone to Go It Alone

The biotech's shares sink more than 13% after the company drops its bid to find a buyer.

Wall Street Shows Mettle

U.S. stocks hold up well after British authorities say they foil a plot to destroy commercial jets.

Stewart Settles SEC Case

The domestic diva will pay $195,000.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Pozen jumps, but ImClone is lower.

Probe Stings Bristol-Myers

The drugmaker tops estimates for the second quarter, but a criminal inquiry weighs on the shares.

Gilead's a Pricey Prospect

Gilead's a Pricey Prospect

Earnings were solid, but cheaper biotechs can be found, including another name that just reported.

Dose of Upside at ImClone

Dose of Upside at ImClone

Erbitux boosts sales.

ImClone's Lonely Quest

ImClone's Lonely Quest

The company has been forsaken in its merger bid, and little suggests that will change.

Still on the Fence

The VIX holds its ground, and the put/call ratio closes above 1 for the fifth time in the last seven sessions.

Weekend Reading: Suffer Fest

Weekend Reading: Suffer Fest

The markets are likely to struggle again next week as Middle Eastern violence only intensifies.

Bristol-Myers Matches Forecast

Abilify, Erbitux and Pravachol post higher sales.

Aversion to Bristol-Myers Ebbs

The drugmaker certainly doesn't have overwhelming support on Wall Street, but a Plavix deal helps.

ImClone Earnings Surge

It easily beats estimates.

ImClone Gets Milestone Payment

ImClone Gets Milestone Payment

The $250 million payment from Bristol-Myers will be the last one under their agreement.

Erbitux Gets Added Approval

Erbitux Gets Added Approval

The ImClone drug gets FDA clearance to treat head and neck cancers.

Funny Money: The Devil Serves Decaf

Don't mess with Starbucks, or the U.S. Congress when it's trying to protect oil industry profits. Plus, much more corporate hilarity!

Icahn Boosts ImClone Stake

He now owns 9.8% of the biotech company.

Erbitux Looks Good in Head-Cancer Study

The ImClone drug and radiation extended patient lives for longer than radiation alone.

Bristol's Not Buying ImClone

The drug giant says in an SEC filing that it has no plan to acquire the Erbitux maker.

Bristol-Myers Eyes Turnaround -- in 2007

Adjusted EPS of 31 cents in the fourth quarter beats estimates.

Slower Growth's Upside

Slower Growth's Upside

A cooling economy may stoke M&A as firms facing slowing sales aim to employ cash.

A Good Omen

A peer's strong earnings bode well for this pick.

ImClone on the Block

ImClone on the Block

The company decides it's time to check out the strategic alternatives scene.

Bristol-Myers Hopes to Settle Vanlev Matter

The company sets up a $185 million reserve to cover an anticipated litigation settlement.

Martha Stewart Conviction Upheld

Bacanovic's case was sent back to a lower court for review.

Health Stocks in Motion

Immucor bleeds after its third-quarter results fall short and the company slashes its outlook.

ImClone CEO Lynch Departs

He resigns by mutual agreement with the drugmaker's board.

Abgenix Ignites on Tumor Trial

Amgen also rises after panitumumab meets its primary endpoint.

Bristol-Myers Tweaks Guidance Down

The drug giant misses third-quarter targets and trims its forecast.